UK ATTR Amyloidosis HTA Strategy Model

NICE's two ATTR-CM stabiliser appraisals set a fully formed precedent, and its shape is the problem for a new entrant. Tafamidis (Vyndaqel/Vyndamax, Pfizer) was recommended under TA696 in 2021 and again under TA984 on 19 June 2024, on a confidential Patient Access Scheme estimated at 40 to 50 percent off UK list, which brings its modelled cost per QALY within the standard £20,000 to £30,000 threshold and an effective NHS price near £12,000 to £18,000 a year, built on the ATTR-ACT trial and a modelled QALY gain of 0.7 to 1.2. Acoramidis (Beyonttra, Bayer) then cleared TA1121 on 14 January 2026 without a head-to-head trial, on an indirect comparison NICE accepted as showing similar clinical effectiveness to tafamidis. Rather than stop at a standard cost-effectiveness sign-off, the committee directed clinicians to prescribe whichever of the two stabilisers is less expensive once administration, dose, price per dose, and each drug's commercial arrangement are accounted for.

That directive rewrites the pricing question for any third stabiliser. Clearing £20,000 to £30,000 per QALY against a single fixed comparator is no longer sufficient, because NICE will simply route prescribers to the cheaper of tafamidis and acoramidis again, and both incumbent prices are hidden behind confidential schemes. A new entrant therefore has to beat an invisible floor it cannot see and that moves with whichever incumbent is cheaper on the day of appraisal. The practical response starts long before the dossier. Formal scientific collaboration with the National Amyloidosis Centre, NICE's appointed clinical expert for every ATTR appraisal to date, is the single highest-return UK investment at roughly £100,000 to £300,000 over two to three years, and parallel investment in the Tc-PYP scintigraphy referral pathway grows the diagnosed pool ahead of submission, since 15,000 to 36,000 of an estimated 20,000 to 40,000 UK ATTRwt-CM patients remain undiagnosed. Our gap register scores the indirect-comparison and confidential-price risks separately, before the model is locked.

Every AXLRx HTA strategy model is built from primary HTA-body sources: NICE technology appraisals and final guidance documents, not secondary summaries. Every comparator claim is pressure-tested through the comparator-defence framework before it is accepted.

UK ATTR-CM HTA sources: NICE TA984 (tafamidis, updating TA696), NICE TA1121 (acoramidis, 14 January 2026), NICE TA1115 (vutrisiran, ATTR-CM), and NICE TA868 (vutrisiran, hereditary ATTR polyneuropathy), with National Amyloidosis Centre epidemiology and NHS England ATTR-CM commissioning documentation.